Related Experiment Video
Updated: Jan 9, 2026
Orthotopic Injection of Breast Cancer Cells into the Mice Mammary Fat Pad
Published on: January 20, 2019
CD301b lectin expression in the breast tumor microenvironment augments tumor growth
Ahmet Ozdilek1, Amy V Paschall1, Zahra Nawaz1
1Department of Biochemistry, Emory Vaccine Center, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322.
Insights
Aberrant tumor glycosylation impacts immune recognition. This study identifies CD301b+ myeloid cells as key drivers of breast tumor growth, suggesting CD301b as a therapeutic target.
Area of Science:
- Immunology
- Cancer Biology
- Glycobiology
Background:
- Aberrant tumor glycosylation influences immune recognition, but its role in tumor progression via glycan-lectin interactions is unclear.
- The tumor microenvironment (TME) plays a critical role in cancer progression and immune evasion.
- Understanding specific glycan-lectin interactions is crucial for developing novel cancer therapies.
Purpose of the Study:
- To investigate the role of C-type lectin receptor CD301b in breast tumor progression.
- To elucidate the function of CD301b+ immune cells within the tumor microenvironment.
- To identify potential therapeutic targets for reprogramming the breast cancer TME.
Main Methods:
- Utilized a murine triple-negative breast cancer model.
- Employed CD301b depletion and genetic knockout strategies.
- Conducted phenotypic analyses, single-cell RNA sequencing, and transcriptomic profiling.
Main Results:
- Tumors expressing the Tn glycoantigen exhibited accelerated growth, facilitated by CD301b+ immune cells.
- Loss or depletion of CD301b significantly suppressed tumor growth, indicating CD301b promotes tumor progression.
- CD301b+ cells were identified as type 2 conventional dendritic cells (cDC2s), and their human ortholog CLEC10A is expressed in human breast cancers.
- Mice lacking Mgl2 (encoding CD301b) showed a shift towards an immune-activated state with enhanced antitumor immunity.
Conclusions:
- CD301b signaling in myeloid cells, particularly cDC2s, promotes breast tumor progression.
- Aberrant tumor glycosylation and CD301b-mediated myeloid cell interactions are critical regulators of the TME.
- CD301b represents a promising therapeutic target for enhancing antitumor immunity in breast cancer.
Abstract:
Aberrant tumor glycosylation can alter immune recognition; however, the specific influence of glycan-lectin interactions on tumor progression remains poorly understood. Here, we identify the C-type lectin receptor CD301b (encoded by Mgl2) as a regulator of immune activity within the breast tumor microenvironment (TME). Using a murine triple-negative breast cancer model, we demonstrate that tumors expressing the Tn glycoantigen grow more rapidly, and this growth is facilitated by CD301b+ immune cells. Depletion or genetic loss of CD301b markedly suppressed tumor growth, indicating that CD301b promotes tumor progression through myeloid-tumor interactions. Phenotypic analyses revealed that CD301b+ cells within tumors are type 2 conventional dendritic cells (cDC2s), a subset known to influence immune polarization. Single-cell RNA sequencing of human breast cancers showed that the human ortholog CLEC10A is expressed in cDC2-like dendritic cells and select macrophage subsets, suggesting a conserved role for CD301+ myeloid populations. Transcriptomic profiling of tumors developed in Mgl2-deficient mice revealed a shift toward an inflammatory, immune-activated state consistent with enhanced antitumor immunity. Together, these findings establish a link between tumor glycosylation and lectin signaling of myeloid cells, highlighting CD301b as a potential target for reprogramming the tumor immune microenvironment in breast cancer.
Related Concept Videos
02:17The Tumor Microenvironment
02:38Mitogens and the Cell Cycle